Search

Displaying results 1361 - 1370 of 1613 in total
  1. Drug

    Padimate O

    go.drugbank.com/drugs/DB11570
    Approved

    Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent ph...

    Mixtures: Care One Cherry SPF 4 Lip Balm, Care One Original SPF 4 Lip BalmProducts: Cap Soleil: Lait Solaire Fps 4
  2. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and ...

  3. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts are collected from the post-auricular biopsy tis...

  4. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    Cantharidin is a naturally occurring odorless, colorless fatty substance of the terpenoid class that is produced as an oral fluid in the alimentary canal of the male blister beetle. For its natural purpose, the male blister beetle secret...

  5. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric

  6. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the … of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.

  7. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood

  8. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    [A177754] Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin

  9. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while avoiding side

  10. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    Additionally, the diverse genetic backgrounds of patients may influence the drug’s effectiveness and side effects.[A263823]